Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology
Incidence of HPV-negative head and neck squamous cell carcinoma
15 evidence topics · 13 sources
Estimated U.S. new cases in 2026, all oral cavity and pharynx cancer
Estimated U.S. new cases in 2026 by subsite, all oral cavity, pharynx, and laryngeal cancer
U.S. incidence rate, all oral cavity and pharynx cancer
U.S. incidence rate, all laryngeal cancer
U.S. incidence trends, all oral cavity and pharynx cancer
U.S. incidence trend of HPV-negative oropharyngeal cancer
“Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV-negative share of U.S. oropharyngeal squamous cell carcinoma
| Oropharynx, United States, 2012 to 2016 | Quoted value |
|---|---|
| Average annual reported cases | “19,000”View highlighted excerpt for this quote |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)”View highlighted excerpt for this quote |
| Attributable to other HPV types, number (%) | “900 (5)”View highlighted excerpt for this quote |
| HPV-negative, number (%) | “5,500 (29)”View highlighted excerpt for this quote |
HPV-positive share in a first-line recurrent or metastatic HNSCC trial population
HPV status among U.S. real-world first-line pembrolizumab recipients with recurrent or metastatic HNSCC
| HPV status, all subtypes | All patients, n (%) | Pembrolizumab monotherapy, n (%) | Pembrolizumab plus chemotherapy, n (%) |
|---|---|---|---|
| Positive | “233 (36.1)”View highlighted excerpt for this quote | “163 (37.8)”View highlighted excerpt for this quote | “70 (32.6)”View highlighted excerpt for this quote |
| Negative | “258 (39.9)”View highlighted excerpt for this quote | “165 (38.3)”View highlighted excerpt for this quote | “93 (43.3)”View highlighted excerpt for this quote |
| Equivocal or unknown | “155 (24.0)”View highlighted excerpt for this quote | “103 (24.9)”View highlighted excerpt for this quote | “52 (24.2)”View highlighted excerpt for this quote |
Company-stated HPV-negative share of recurrent or metastatic HNSCC
Median age at diagnosis by etiology, all HNSCC
Global new cases in 2024 by subsite, all histologies
| GLOBOCAN 2024 cancer site | New cases | Percentage of all cases |
|---|---|---|
| Lip, oral cavity | “452,205”View highlighted excerpt for this quote | “2.2”View highlighted excerpt for this quote |
| Larynx | “193,937”View highlighted excerpt for this quote | “0.9”View highlighted excerpt for this quote |
| Oropharynx | “107,887”View highlighted excerpt for this quote | “0.5”View highlighted excerpt for this quote |
| Hypopharynx | “91,464”View highlighted excerpt for this quote | “0.4”View highlighted excerpt for this quote |
Metastatic disease at diagnosis and recurrence after initial therapy, all HNSCC
Recurrence after primary treatment of locoregionally advanced HNSCC in U.S. adults aged 66 years or older
“In the resected cohort, 333 patients (66%) experienced recurrence following their primary treatment, compared with 169 (34%) who remained recurrence-free throughout the follow-up period. In the unresected cohort, 791 patients (65%) developed recurrence and 426 did not (35%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote